Siga Technologies ( (SIGA) ) has released its Q3 earnings. Here is a breakdown of the information Siga Technologies presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company specializing in the development of antiviral medicines to combat infectious diseases, with a primary focus on orthopoxviruses. The company is known for its flagship product, TPOXX, which is approved for the treatment of smallpox and other related diseases in various countries.
In its latest earnings report, SIGA Technologies announced financial results for the three and nine months ending September 30, 2025. The company reported $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of the year. The CEO emphasized the company’s ongoing efforts to secure new procurement contracts with the U.S. and international governments.
Key financial highlights include a significant increase in product sales, which reached $85.8 million for the nine-month period, up from $53.5 million in the previous year. Despite this growth, the company faced a net loss of $6.4 million for the third quarter, attributed to a decrease in quarterly revenues and increased research and development expenses. Notably, SIGA’s TPOXX product secured regulatory approval in Japan, marking a significant milestone for the company’s international expansion.
Looking ahead, SIGA Technologies remains focused on expanding its partnerships and securing additional contracts to bolster its revenue base. The management is optimistic about building on its track record of successful collaborations with government entities to support its growth in the coming years.